In the first-ever efficacy trial of antiretroviral-based pre-exposure prophylaxis, once-daily oral tenofovir significantly reduced the risk for HIV acquisition among men who have sex with men. The use ...
Friday, May 20, 2022 (San Diego, U.S.)—Research from the University of California released in Clinical Infectious Diseases demonstrates that ingestible sensor-enabled Truvada®, taken as pre-exposure ...
(RTTNews) - Gilead Sciences, Inc. (GILD) said Tuesday that the China National Medical Products Administration or NMPA has approved a pre-exposure prophylaxis indication for its blockbuster HIV drug ...
Tenofovir decreases HSV-2 risk Oral tenofovir-based prophylaxis for HIV also reduced herpes simplex virus-2 transmission. Daily oral tenofovir-based preexposure prophylaxis (PrEP) for HIV also seemed ...
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for DESCOVY® (emtricitabine 200 mg and ...
Approximately 2% of adolescents at risk for HIV filled a preexposure prophylaxis (PrEP) prescription from 2018 to 2022 in the ...
The rising cost of Gilead’s Truvada may be a key factor in why the HIV prevention drug has not been widely used, according to an analysis published in the Annals of Internal Medicine. Truvada, also ...
About 48,100 new HIV infections occur annually in the United States, 61% of which occur in men who have sex with men (MSM). [1] Antiretroviral preexposure prophylaxis (PrEP) is an exciting new tool ...
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results